GeoVax investor reports 4.99% beneficial ownership
GeoVax Labs, Inc. is reported to have 387,038 shares of its common stock beneficially owned by Armistice Capital, LLC and Steven Boyd, representing 4.99% of the outstanding class as of June 30, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
GeoVax Labs, Inc. is reported to have 387,038 shares of its common stock beneficially owned by Armistice Capital, LLC and Steven Boyd, representing 4.99% of the outstanding class as of June 30, 2026. All of these shares are held with shared voting and dispositive power; neither reporting person has sole voting or dispositive authority. Armistice Capital serves as investment manager to Armistice Capital Master Fund Ltd., the direct holder of the shares, and may be deemed to beneficially own the securities held by the Master Fund. Steven Boyd, as managing member of Armistice Capital, may also be deemed a beneficial owner, while the Master Fund has the right to receive dividends and sale proceeds.
Key Figures
Key Terms
beneficially own financial
Investment Management Agreement financial
Schedule 13G regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake in GeoVax Labs, Inc. (GOVX) does Armistice Capital report in this Schedule 13G/A?
Who are the reporting persons in the GeoVax Labs (GOVX) Schedule 13G/A Amendment No. 4?
Why does the filing state ownership of 5 percent or less of GeoVax (GOVX) stock?
What role does Armistice Capital Master Fund Ltd. have in the GeoVax (GOVX) position?
AI-generated analysis. How Rhea-AI works. Not financial advice.